Radioligand Therapy (RLT) Market - Global Forecast to 2035
商品番号 : SMB-87858
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年9月 |
| ページ数 | 313 |
| 図表数 | 418 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
放射性リガンド療法（RLT）市場 – 製品（ルテチウム-177ビピボチドテトラキセタン、（Lu-177）-PNT2002、ラジウム-223二塩化物）、標的（PSMA、SSTR、骨転移）、適応症（前立腺癌、神経内分泌腫瘍（NETS）、SCLC） – 2035年までの世界予測
世界の放射性リガンド療法市場は、2025年の推定31億5,000万米ドルから2035年には109億1,000万米ドルに達し、予測期間中に13.2%の年平均成長率（CAGR）で成長すると予測されています。放射性リガンド療法市場の成長は、主にRLT製品の承認取得と適応拡大の増加、特にLu-177供給における製造規模の拡大、患者選択におけるPSMAおよびSSTR PETイメージングの採用増加、そしてより幅広い患者アクセスを支援する保険償還範囲の拡大によって牽引されています。
この調査レポートでは、放射性リガンド療法市場を、製品（ルテチウム-177ビピボチドテトラキセタン、ルテチウム-177ドータテート、ラジウム-223ジクロリド、（LU-177）-PNT2002、225AC-PSMA-617、FPI-2265/ 225 AC PSMA – I&T、I-131-1095、TLX591（177LUロソパタマブテトラキセタン）、アルファメディックス（²¹²PB-ドータテート）、67CU-SAR-BISPSMA、およびその他の製品）、ターゲット（PSMA、SSTR、およびその他のターゲット）、適応症（前立腺がん、神経内分泌腫瘍、およびその他の適応症）、エンドユーザー（三次医療の大学/総合がんセンター、専門核医学センター、およびその他のエンドユーザー）、地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ)。
本レポートは、放射性リガンド療法市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの徹底的な分析により、事業概要、製品、ソリューション、主要戦略、提携、パートナーシップ、契約、新規承認／発売、提携、買収、そして放射性リガンド療法市場に関連する最近の動向に関する洞察が得られています。
本レポートは、放射性リガンド療法市場とそのサブセグメントの収益数値を最も近似値で示すことで、市場リーダー企業と新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。
The global radioligand therapy market is projected to reach USD 10.91 billion by 2035 from an estimated USD 3.15 billion in 2025, at a CAGR of 13.2% during the forecast period. The growth of the radioligand therapy market is majorly driven by increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, rising adoption of PSMA and SSTR PET imaging for patient selection, and expanding reimbursement coverage supporting broader patient access.
By target, the prostate-specific membrane antigen segment accounted for the largest market share in 2024.
Based on target, the market is categorized into Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), and other targets. The Prostate-Specific Membrane Antigen (PSMA) segment accounted for the largest share of the market in 2024. The large share of this segment is attributed to its high expression in prostate cancer cells and its minimal presence in normal tissues. This makes PSMA an ideal biomarker for precision oncology, enabling accurate patient selection and effective therapy delivery. The success of PSMA-targeted treatments, such as Pluvicto (lutetium-177 vipivotide tetraxetan), has reinforced its dominance, particularly in metastatic castration-resistant prostate cancer (mCRPC).
By product, the Lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market in 2024.
By product, the market is segmented into Lutetium‑177 Vipivotide Tetraxetan, Lutetium-177 Dotatate, Radium-223 Dichloride, [LU-177]-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA – I&T, I-131-1095, TLX591 (177LU Rosopatamab Tetraxetan), Alphamedix (²¹²PB-DOTAMTATE), 67CU‑SAR‑BISPSMA, and other products. In 2024, the lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market. Developed and commercialized by Novartis, Lutetium-177 vipivotide tetraxetan (Pluvicto) targets Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed in prostate cancer cells, making it a precision therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Since its FDA and EMA approvals, the therapy has become widely adopted due to its ability to extend survival and improve quality of life in patients with limited treatment options. Its use of lutetium-177 enables targeted beta radiation delivery, sparing surrounding healthy tissues while maximizing tumor control.
By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period.
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include the rising cancer incidence, improvements in healthcare infrastructure, and increasing awareness of precision oncology solutions. Countries such as China, Japan, South Korea, India, and Australia are witnessing the growing adoption of nuclear medicine, which is supported by expanding diagnostic capabilities and investments in theragnostic. Governments & private institutions are actively investing in isotope production facilities, addressing long-standing supply challenges for key isotopes like lutetium-177 and actinium-225, essential for commercialized and pipeline RLT products. Regulatory authorities in the region also show greater receptivity to radiopharmaceutical approvals, creating a favourable environment for clinical development and faster patient access.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side- 30%
- By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25%
- By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%
Key Companies
The key players in the radioligand therapy market include Novartis AG (Switzerland), Bayer AG (Germany), Curium US LLC (US), Eli Lilly and Company (US), AstraZeneca plc (UK), Progenics Pharmaceuticals, Inc. (US), Ariceum Therapeutics GmbH (Germany), Telix Pharmaceuticals Limited (Australia), ITM Isotope Technologies Munich SE (Germany), Convergent Therapeutics, Inc. (US), Orano Med SAS (France), Actinium Pharmaceuticals, Inc. (US), Perspective Therapeutics, Inc. (US), Clarity Pharmaceuticals Ltd. (Australia), and Radiopharm Theranostics Ltd. (Australia), among others.
Research Coverage
This research report categorizes the radioligand therapy market, by product [Lutetium-177 vipivotide tetraxetan, LUTETIUM-177 DOTATATE, Radium-223 dichloride, (LU-177)-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA – I&T, I-131-1095, TLX591 (177LU ROSOPATAMAB TETRAXETAN), ALPHAMEDIX (²¹²PB-DOTAMTATE), 67CU‑SAR‑BISPSMA, and other products), target (PSMA, SSTR, and other targets), indication (prostate cancer, neuroendocrine tumors, and other indications), and end user (tertiary care academic/comprehensive cancer centers, specialized nuclear medicine centers, and other end user), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa).
The report’s scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the radioligand therapy market. A thorough analysis of the key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements: new approvals/launches, collaborations, acquisitions, and recent developments associated with the radioligand therapy market.
Reasons to buy this report
The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the radioligand therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, the rising adoption of PSMA and SSTR PET imaging for patient selection. Expanding reimbursement coverage supporting broader patient access), restraints (Isotope scarcity for Lu-177 and Ac-225 creating supply bottlenecks, complex regulatory requirements for handling & licensing radioactive materials, logistical hurdles & half-life constraints limiting distribution), opportunities [advancements of alpha therapies (Ac-225, Pb-212) with strong clinical potential, expansion into earlier-line and adjuvant use, broadening eligible populations, combination regimens with immuno-oncology, PARP inhibitors, and other targeted agents), and challenges (reactor outages and geopolitical risks impacting isotope production & supply chains and the growing competition from alternative modalities such as ADCs and bispecific antibodies)
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the radioligand therapy market
- Market Development: Comprehensive information about lucrative markets across varied regions
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the radioligand therapy market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the radioligand therapy market.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.3 STUDY SCOPE 32
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 32
1.3.2 INCLUSIONS AND EXCLUSIONS 33
1.3.3 YEARS CONSIDERED 33
1.4 CURRENCY CONSIDERED 34
1.5 STAKEHOLDERS 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Objectives of secondary research 36
2.1.1.2 Key data from secondary sources 37
2.1.2 PRIMARY DATA 37
2.1.2.1 Breakdown of primaries 38
2.1.2.2 Key objectives of primary research 38
2.2 MARKET SIZE ESTIMATION 39
2.2.1 GLOBAL MARKET ESTIMATION 39
2.2.1.1 Company revenue analysis (Bottom-up approach) 39
2.2.1.2 Revenue share analysis 40
2.2.1.3 MnM repository analysis 41
2.2.1.4 Primary interviews 41
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 42
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 42
2.3 GROWTH RATE PROJECTIONS 44
2.4 DATA TRIANGULATION 46
2.5 RESEARCH ASSUMPTIONS 47
2.6 RESEARCH LIMITATIONS 47
2.7 RISK ANALYSIS 48
3 EXECUTIVE SUMMARY 49
3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 49
3.1.1 BIOTECH STARTUPS AND INNOVATIVE COMPANIES 49
3.1.2 ESTABLISHED MARKET LEADERS 50
3.1.3 CDMOS AND CROS 50
4 PREMIUM INSIGHTS 55
4.1 RADIOLIGAND THERAPY MARKET OVERVIEW 55
4.2 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT AND COUNTRY, 2025 56
4.3 RADIOLIGAND THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 57
4.4 RADIOLIGAND THERAPY MARKET: EMERGING VS. DEVELOPED MARKETS 58
4.5 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 58
4.6 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT 59
4.7 VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE 59
4.8 REGULATORY POLICY INITIATIVES 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 61
5.2.1 DRIVERS 62
5.2.1.1 Increasing approvals and label expansion of RLT products 62
5.2.1.2 Manufacturing scale-up of Lu-177 63
5.2.1.3 Rising adoption of prostate-specific membrane antigen and somatostatin receptor PET imaging 63
5.2.1.4 Expanding reimbursement coverage 63
5.2.2 RESTRAINTS 64
5.2.2.1 Isotope supply scarcity 64
5.2.2.2 Stringent regulatory requirements 64
5.2.2.3 Logistical hurdles and half-life constraints 64
5.2.3 OPPORTUNITIES 65
5.2.3.1 Advancements in alpha therapies 65
5.2.3.2 Expansion of radioligand therapy into earlier-line and adjuvant settings 65
5.2.3.3 Combination regimens integrating radioligand therapy 66
5.2.4 CHALLENGES 66
5.2.4.1 Reactor outages and geopolitical risks 66
5.2.4.2 Growing competition from alternative modalities 66
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 67
5.4 PRICING ANALYSIS 68
5.4.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024 68
5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION 69
5.5 VALUE CHAIN ANALYSIS 70
5.6 ECOSYSTEM ANALYSIS 71
5.7 INVESTMENT AND FUNDING SCENARIO 73
5.8 TECHNOLOGY ANALYSIS 74
5.8.1 KEY TECHNOLOGIES 74
5.8.1.1 Beta-emitting therapeutic radionuclides 74
5.8.1.2 Alpha-emitting therapeutic radionuclides 74
5.8.1.3 Targeting ligands 74
5.8.1.4 Monoclonal antibody-directed radiotherapeutics 75
5.8.2 COMPLEMENTARY TECHNOLOGIES 75
5.8.2.1 SPECT/CT and PET/CT 75
5.8.2.2 Alternative isotopes 75
5.8.3 ADJACENT TECHNOLOGIES 75
5.8.3.1 Antibody drug conjugates 75
5.8.3.2 Bispecific antibodies 76
5.9 KEY CONFERENCES AND EVENTS, 2025–2027 76
5.10 REGULATORY LANDSCAPE 77
5.10.1 REGULATORY ANALYSIS 77
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
5.11 PORTER’S FIVE FORCES ANALYSIS 81
5.11.1 BARGAINING POWER OF SUPPLIERS 82
5.11.2 BARGAINING POWER OF BUYERS 82
5.11.3 THREAT OF NEW ENTRANTS 82
5.11.4 THREAT OF SUBSTITUTES 82
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 82
5.12 KEY STAKEHOLDERS AND BUYING PROCESS 83
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
5.12.2 BUYING CRITERIA 84
5.13 MACROECONOMICS INDICATORS 85
5.13.1 HEALTHCARE EXPENDITURE TRENDS 85
5.13.2 GLOBAL CANCER BURDEN 87
5.14 PIPELINE ANALYSIS 88
5.15 UNMET NEEDS AND WHITE SPACES 89
5.16 IMPACT OF AI/GEN AI ON RADIOLIGAND THERAPY MARKET 90
5.16.1 INTRODUCTION 90
5.16.2 MARKET POTENTIAL OF AI IN RADIOLIGAND THERAPY APPLICATIONS 90
5.16.3 AI USE CASES 91
5.17 IMPACT OF 2025 US TARIFF 92
5.17.1 INTRODUCTION 92
5.17.2 KEY TARIFF RATES 92
5.17.3 PRICE IMPACT ANALYSIS 93
5.17.4 IMPACT ON COUNTRY/REGION 94
5.17.4.1 US 94
5.17.4.2 Europe 94
5.17.4.3 Asia Pacific 95
5.17.4.4 Rest of the World 95
5.17.5 IMPACT ON MANUFACTURING INDUSTRY 96
6 RADIOLIGAND THERAPY MARKET, BY PRODUCT 97
6.1 INTRODUCTION 98
6.2 LUTETIUM 177 VIPIVOTIDE TETRAXETAN 98
6.2.1 BROADER REGULATORY ACCEPTANCE AND EXPANDING PAYER COVERAGE TO AID GROWTH 98
6.3 LUTETIUM-177 DOTATATE 102
6.3.1 INCREASING RECOGNITION OF LUTETIUM-177 DOTATATE IN TREATING GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO BOOST MARKET 102
6.4 RADIUM-223 DICHLORIDE 105
6.4.1 INCREASING ADOPTION OF RADIUM-223 DICHLORIDE IN EMERGING MARKETS TO STIMULATE GROWTH 105
6.5 LU-177 PNT2002 109
6.5.1 STRONG PHASE III CLINICAL VALIDATION AND STRATEGIC COMMERCIALIZATION PARTNERSHIPS TO SPUR GROWH 109
6.6 ²²⁵AC-PSMA-617 112
6.6.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO BOLSTER GROWTH 112
6.7 FPI-2265 115
6.7.1 EARLY RESPONSE DATA AND SAFETY REASSURANCE TO AMPLIFY GROWTH 115
6.8 I-131-1095 119
6.8.1 FAVORABLE DOSIMETRY AND SAFETY PROFILES TO SUSTAIN GROWTH 119
6.9 TLX591 122
6.9.1 SIMPLIFIED DOSING REGIMEN AND FAVORABLE TOLERABILITY TO DRIVE MARKET 122
6.10 ALPHAMEDIX ( ²¹²PB-DOTAMTATE) 125
6.10.1 ROBUST EARLY-PHASE EFFICACY AND STRONG COMMERCIALIZATION TO SUPPORT GROWTH 125
6.11 67CU-SAR-BISPSMA 129
6.11.1 ENHANCED LESION UPTAKE & RETENTION AND FAVORABLE TOLERABILITY PROFILE TO FOSTER GROWTH 129
6.12 OTHER PRODUCTS 132
7 RADIOLIGAND THERAPY MARKET, BY TARGET 136
7.1 INTRODUCTION 137
7.2 PROSTATE-SPECIFIC MEMBRANE ANTIGEN 137
7.2.1 STRONG BIOLOGICAL RATIONALE, ROBUST CLINICAL OUTCOMES, AND RAPID SCALING OF GLOBAL SUPPLY CHAINS TO PROMOTE GROWTH 137
7.3 SOMATOSTATIN RECEPTOR 141
7.3.1 PROVEN EFFICACY IN TREATING NEUROENDOCRINE TUMORS TO EXPEDITE GROWTH 141
7.4 OTHER TARGETS 144
8 RADIOLIGAND THERAPY MARKET, BY INDICATION 148
8.1 INTRODUCTION 149
8.2 PROSTATE CANCER 149
8.2.1 EXPANDING TREATMENT POPULATIONS AND CLINICAL VALIDATION TO ENCOURAGE GROWTH 149
8.3 NEUROENDOCRINE TUMORS 153
8.3.1 REGULATORY ADVANCEMENTS AND STRATEGIC INDUSTRY MOVES TO FACILITATE GROWTH 153
8.4 OTHER INDICATIONS 156
9 RADIOLIGAND THERAPY MARKET, BY END USER 160
9.1 INTRODUCTION 161
9.2 TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS 161
9.2.1 ADVANCED TREATMENT DELIVERY AND CLINICAL TRIAL CAPABILITIES TO CONTRIBUTE TO GROWTH 161
9.3 SPECIALIZED NUCLEAR MEDICINE CENTERS 165
9.3.1 HIGHLY TRAINED PERSONNEL AND TARGETED FACILITIES TO ACCELERATE GROWTH 165
9.4 OTHER END USERS 169
10 RADIOLIGAND THERAPY MARKET, BY REGION 173
10.1 INTRODUCTION 174
10.2 NORTH AMERICA 174
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 175
10.2.2 US 179
10.2.2.1 Robust ecosystem of biotech innovation and strong academic-industry collaboration to spur growth. 179
10.2.3 CANADA 181
10.2.3.1 Growing clinical trial momentum to drive market 181
10.3 EUROPE 183
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 183
10.3.2 GERMANY 186
10.3.2.1 Strong clinical advancements and active industry partnerships to foster growth. 186
10.3.3 UK 188
10.3.3.1 Growing efforts for decentralized access and innovations to boost market 188
10.3.4 FRANCE 190
10.3.4.1 Strong nuclear medicine manufacturing and isotope supply foundation to bolster growth 190
10.3.5 ITALY 192
10.3.5.1 Rising preclinical exploration and early discovery stages to stimulate growth 192
10.3.6 SPAIN 194
10.3.6.1 Established nuclear-medicine departments and authorized radiopharmacy frameworks to aid growth 194
10.3.7 REST OF EUROPE 196
10.4 ASIA PACIFIC 199
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 199
10.4.2 CHINA 203
10.4.2.1 Favorable regulatory reforms and expanding hospital-based nuclear medicine capabilities to amplify growth 203
10.4.3 JAPAN 205
10.4.3.1 Academic excellence, manufacturing expansion, and supportive regulation to contribute to growth 205
10.4.4 INDIA 207
10.4.4.1 Lower trial costs and skilled medical professionals to accelerate growth 207
10.4.5 SOUTH KOREA 209
10.4.5.1 Growing emphasis on nuclear medicine innovation to propel market 209
10.4.6 AUSTRALIA 211
10.4.6.1 Need to maintain high standards of quality, compliance, and innovation to facilitate growth 211
10.4.7 REST OF ASIA PACIFIC 213
10.5 LATIN AMERICA 215
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 215
10.5.2 BRAZIL 218
10.5.2.1 Favorable educational initiatives and expanding biopharma infrastructure to promote growth 218
10.5.3 MEXICO 220
10.5.3.1 Growing cyclotron capacity to fuel market 220
10.5.4 REST OF LATIN AMERICA 222
10.6 MIDDLE EAST 225
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 225
10.6.2 GCC COUNTRIES 228
10.6.3 SAUDI ARABIA 231
10.6.3.1 Growing initiatives for healthcare and life sciences sectors to drive market 231
10.6.4 UAE 233
10.6.4.1 Emerging biotechnology sector to intensify growth 233
10.6.5 REST OF GCC COUNTRIES 235
10.6.6 REST OF MIDDLE EAST 237
10.7 AFRICA 239
10.7.1 ENHANCED CLINICAL TRIAL ECOSYSTEM AND REGULATORY REFORMS TO AID GROWTH 239
10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 239
11 COMPETITIVE LANDSCAPE 242
11.1 INTRODUCTION 242
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 242
11.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 242
11.4 REVENUE ANALYSIS, 2028–2030 243
11.5 MARKET SHARE ANALYSIS, 2030 244
11.6 COMPANY VALUATION AND FINANCIAL METRICS 246
11.7 BRAND/PRODUCT COMPARISON 247
11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 248
11.8.1 STARS 248
11.8.2 EMERGING LEADERS 248
11.8.3 PERVASIVE PLAYERS 248
11.8.4 PARTICIPANTS 248
11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 250
11.8.5.1 Region footprint 251
11.8.5.2 Target footprint 252
11.8.5.3 Indication footprint 252
11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 253
11.9.1 PROGRESSIVE COMPANIES 253
11.9.2 RESPONSIVE COMPANIES 253
11.9.3 DYNAMIC COMPANIES 253
11.9.4 STARTING BLOCKS 253
11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 255
11.9.5.1 Detailed list of key startups/SMEs 255
11.9.5.2 Competitive benchmarking of key startups/SMEs 256
11.10 COMPETITIVE SCENARIO 257
11.10.1 PRODUCT LAUNCHES AND APPROVALS 257
11.10.2 DEALS 258
11.10.3 EXPANSIONS 259
12 COMPANY PROFILES 260
12.1 KEY PLAYERS 260
12.1.1 NOVARTIS AG 260
12.1.1.1 Business overview 260
12.1.1.2 Products offered 261
12.1.1.3 Products in pipeline 262
12.1.1.4 Recent developments 262
12.1.1.4.1 Product launches and approvals 262
12.1.1.4.2 Deals 262
12.1.1.4.3 Expansions 263
12.1.1.5 MnM view 263
12.1.1.5.1 Key strengths 263
12.1.1.5.2 Strategic choices 263
12.1.1.5.3 Weaknesses and competitive threats 264
12.1.2 BAYER AG 265
12.1.2.1 Business overview 265
12.1.2.2 Products offered 266
12.1.2.2.1 Deals 267
12.1.2.2.2 Other developments 267
12.1.2.3 MnM view 267
12.1.2.3.1 Key strengths 267
12.1.2.3.2 Strategic choices 267
12.1.2.3.3 Weaknesses and competitive threats 268
12.1.3 CURIUM US LLC 269
12.1.3.1 Business overview 269
12.1.3.2 Products in pipeline 269
12.1.3.3 Recent developments 269
12.1.3.3.1 Deals 269
12.1.3.4 MnM view 270
12.1.3.4.1 Key strengths 270
12.1.3.4.2 Strategic choices 270
12.1.3.4.3 Weaknesses and competitive threats 270
12.1.4 ELI LILLY AND COMPANY 271
12.1.4.1 Business overview 271
12.1.4.2 Products in pipeline 272
12.1.4.3 Recent developments 273
12.1.4.3.1 Product launches and approvals 273
12.1.4.3.2 Deals 273
12.1.4.4 MnM view 273
12.1.4.4.1 Key strengths 273
12.1.4.4.2 Strategic choices 273
12.1.4.4.3 Weaknesses and competitive threats 274
12.1.5 ASTRAZENECA 275
12.1.5.1 Business overview 275
12.1.5.2 Products in pipeline 276
12.1.5.3 Recent developments 277
12.1.5.3.1 Deals 277
12.1.5.4 MnM view 277
12.1.5.4.1 Key strengths 277
12.1.5.4.2 Strategic choices 277
12.1.5.4.3 Weaknesses and competitive threats 277
12.1.6 PROGENICS PHARMACEUTICALS INC. (LANTHEUS) 278
12.1.6.1 Business overview 278
12.1.6.2 Products in pipeline 279
12.1.6.3 Recent developments 279
12.1.6.3.1 Deals 279
12.1.7 ARICEUM THERAPEUTICS 280
12.1.7.1 Products in pipeline 280
12.1.7.2 Recent developments 280
12.1.7.2.1 Deals 280
12.1.8 TELIX PHARMACEUTICALS 281
12.1.8.1 Business overview 281
12.1.8.2 Products in pipeline 282
12.1.8.3 Recent developments 283
12.1.8.3.1 Deals 283
12.1.8.3.2 Expansions 283
12.1.8.3.3 Other developments 283
12.1.9 ITM ISOTOPE TECHNOLOGIES 284
12.1.9.1 Business overview 284
12.1.9.2 Products offered 284
12.1.9.3 Recent developments 285
12.1.9.3.1 Deals 285
12.1.9.3.2 Expansions 286
12.1.10 CONVERGENT THERAPEUTICS, INC. 287
12.1.10.1 Business overview 287
12.1.10.2 Products in pipeline 287
12.1.10.3 Recent developments 287
12.1.10.3.1 Product launches and approvals 287
12.1.10.3.2 Deals 288
12.1.11 ORANO SA 289
12.1.11.1 Business overview 289
12.1.11.2 Products in pipeline 290
12.1.11.3 Recent developments 291
12.1.11.3.1 Deals 291
12.1.11.3.2 Expansions 291
12.1.12 ACTINIUM PHARMACEUTICALS, INC. 292
12.1.12.1 Business overview 292
12.1.12.2 Products in pipeline 293
12.1.12.3 Recent developments 293
12.1.12.3.1 Product launches and approvals 293
12.1.12.3.2 Deals 293
12.1.13 PERSPECTIVE THERAPEUTICS, INC. 294
12.1.13.1 Business overview 294
12.1.13.2 Products in pipeline 294
12.1.13.3 Recent developments 295
12.1.13.3.1 Deals 295
12.1.14 CLARITY PHARMACEUTICALS 296
12.1.14.1 Business overview 296
12.1.14.2 Products in pipeline 297
12.1.14.3 Recent developments 297
12.1.14.3.1 Deals 297
12.1.14.3.2 Other developments 297
12.1.15 RADIOPHARM THERANOSTICS LTD. 298
12.1.15.1 Business overview 298
12.1.15.2 Products in pipeline 298
12.1.15.3 Recent developments 299
12.1.15.3.1 Deals 299
12.2 OTHER PLAYERS 300
12.2.1 ALPHA 9 ONCOLOGY 300
12.2.2 RATIO THERAPEUTICS 300
12.2.3 NORIA THERAPEUTICS 301
12.2.4 PRECIRIX 301
12.2.5 SOFIE 302
12.2.6 ECKERT & ZIEGLER RADIOPHARMA 302
12.2.7 NORTHSTAR MEDICAL RADIOISOTOPES, LLC 303
12.2.8 IRE- IRE ELIT 303
12.2.9 BWXT MEDICAL LTD. 304
12.2.10 NTP RADIOISOTOPES 304
13 APPENDIX 305
13.1 DISCUSSION GUIDE 305
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 309
13.3 CUSTOMIZATION OPTIONS 311
13.4 RELATED REPORTS 311
13.5 AUTHOR DETAILS 312
LIST OF TABLES
TABLE 1 RADIOLIGAND THERAPY MARKET: INCLUSIONS AND EXCLUSIONS 33
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 45
TABLE 3 RADIOLIGAND THERAPY MARKET: RISK ANALYSIS 48
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FOR RADIOPHARMACEUTICAL MOLECULES BY REGION, 2023–2030 (USD BILLION) 59
TABLE 5 RADIOLIGAND THERAPY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 62
TABLE 6 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY KEY PLAYER, 2024 69
TABLE 7 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS,
BY REGION, 2024 70
TABLE 8 RADIOLIGAND THERAPY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 72
TABLE 9 RADIOLIGAND THERAPY MARKET: KEY CONFERENCES AND EVENTS, 2025–2027 76
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 14 RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 81
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND
THERAPY PRODUCTS (%) 83
TABLE 16 KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY, BY END USER 84
TABLE 17 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP) 86
TABLE 18 US: CANCER INCIDENCE, BY STATE, 2024 87
TABLE 19 RADIOLIGAND THERAPY PRODUCTS IN CLINICAL PIPELINE, 2025–2032 88
TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES 92
TABLE 21 RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 98
TABLE 22 RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN,
BY REGION, 2023–2035 (USD MILLION) 99
TABLE 23 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 99
TABLE 24 EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 100
TABLE 25 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 100
TABLE 26 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 101
TABLE 27 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY REGION, 2023–2035 (USD MILLION) 101
TABLE 28 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 101
TABLE 29 RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023–2035 (USD MILLION) 102
TABLE 30 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION) 103
TABLE 31 EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE,
BY COUNTRY, 2023–2035 (USD MILLION) 103
TABLE 32 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE,
BY COUNTRY, 2023–2035 (USD MILLION) 104
TABLE 33 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION) 104
TABLE 34 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE,
BY REGION, 2023–2035 (USD MILLION) 104
TABLE 35 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION) 105
TABLE 36 RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023–2035 (USD MILLION) 106
TABLE 37 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION) 106
TABLE 38 EUROPE: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE,
BY COUNTRY, 2023–2035 (USD MILLION) 107
TABLE 39 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE,
BY COUNTRY, 2023–2035 (USD MILLION) 107
TABLE 40 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION) 108
TABLE 41 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023–2035 (USD MILLION) 108
TABLE 42 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION) 108
TABLE 43 RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY REGION,
2023–2035 (USD MILLION) 109
TABLE 44 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY COUNTRY, 2023–2035 (USD MILLION) 109
TABLE 45 EUROPE: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION) 110
TABLE 46 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY COUNTRY, 2023–2035 (USD MILLION) 110
TABLE 47 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY COUNTRY, 2023–2035 (USD MILLION) 111
TABLE 48 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY REGION, 2023–2035 (USD MILLION) 111
TABLE 49 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY COUNTRY, 2023–2035 (USD MILLION) 111
TABLE 50 RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617, BY REGION,
2023–2035 (USD MILLION) 112
TABLE 51 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617,
BY COUNTRY, 2023–2035 (USD MILLION) 113
TABLE 52 EUROPE: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION) 113
TABLE 53 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617,
BY COUNTRY, 2023–2035 (USD MILLION) 114
TABLE 54 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617,0
BY COUNTRY, 2023–2035 (USD MILLION) 114
TABLE 55 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617, BY REGION, 2023–2035 (USD MILLION) 114
TABLE 56 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617,
BY COUNTRY, 2023–2035 (USD MILLION) 115
TABLE 57 RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION,
2023–2035 (USD MILLION) 116
TABLE 58 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION) 116
TABLE 59 EUROPE: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY,
2023–2035 (USD MILLION) 117
TABLE 60 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION) 117
TABLE 61 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION) 118
TABLE 62 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION,
2023–2035 (USD MILLION) 118
TABLE 63 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION) 118
TABLE 64 RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION,
2023–2035 (USD MILLION) 119
TABLE 65 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION) 119
TABLE 66 EUROPE: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY,
2023–2035 (USD MILLION) 120
TABLE 67 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION) 120
TABLE 68 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION) 121
TABLE 69 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023–2035 (USD MILLION) 121
TABLE 70 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION) 121
TABLE 71 RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION,
2023–2035 (USD MILLION) 122
TABLE 72 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION) 123
TABLE 73 EUROPE: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY,
2023–2035 (USD MILLION) 123
TABLE 74 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY,
2023–2035 (USD MILLION) 124
TABLE 75 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION) 124
TABLE 76 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION,
2023–2035 (USD MILLION) 124
TABLE 77 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION) 125
TABLE 78 RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY REGION,
2023–2035 (USD MILLION) 126
TABLE 79 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE,
BY COUNTRY, 2023–2035 (USD MILLION) 126
TABLE 80 EUROPE: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION) 127
TABLE 81 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE,
BY COUNTRY, 2023–2035 (USD MILLION) 127
TABLE 82 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE,
BY COUNTRY, 2023–2035 (USD MILLION) 128
TABLE 83 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE,
BY REGION, 2023–2035 (USD MILLION) 128
TABLE 84 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE,
BY COUNTRY, 2023–2035 (USD MILLION) 128
TABLE 85 RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY REGION,
2023–2035 (USD MILLION) 129
TABLE 86 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY COUNTRY, 2023–2035 (USD MILLION) 130
TABLE 87 EUROPE: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION) 130
TABLE 88 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY COUNTRY, 2023–2035 (USD MILLION) 131
TABLE 89 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY COUNTRY, 2023–2035 (USD MILLION) 131
TABLE 90 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY REGION, 2023–2035 (USD MILLION) 131
TABLE 91 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA,
BY COUNTRY, 2023–2035 (USD MILLION) 132
TABLE 92 RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION,
2023–2035 (USD MILLION) 132
TABLE 93 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023–2035 (USD MILLION) 133
TABLE 94 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION) 133
TABLE 95 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023–2035 (USD MILLION) 134
TABLE 96 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023–2035 (USD MILLION) 134
TABLE 97 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY REGION, 2023–2035 (USD MILLION) 134
TABLE 98 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023–2035 (USD MILLION) 135
TABLE 99 RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 137
TABLE 100 RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION) 138
TABLE 101 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 138
TABLE 102 EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 139
TABLE 103 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 139
TABLE 104 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 140
TABLE 105 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION) 140
TABLE 106 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 140
TABLE 107 RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION) 141
TABLE 108 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION) 142
TABLE 109 EUROPE: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR,
BY COUNTRY, 2023–2035 (USD MILLION) 142
TABLE 110 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION) 143
TABLE 111 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION) 143
TABLE 112 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION) 143
TABLE 113 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION) 144
TABLE 114 RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION,
2023–2035 (USD MILLION) 145
TABLE 115 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS,
BY COUNTRY, 2023–2035 (USD MILLION) 145
TABLE 116 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION) 146
TABLE 117 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS,
BY COUNTRY, 2023–2035 (USD MILLION) 146
TABLE 118 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS,
BY COUNTRY, 2023–2035 (USD MILLION) 147
TABLE 119 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION) 147
TABLE 120 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS,
BY REGION, 2023–2035 (USD MILLION) 147
TABLE 121 RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 149
TABLE 122 RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION,
2023–2035 (USD MILLION) 150
TABLE 123 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023–2035 (USD MILLION) 150
TABLE 124 EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION) 151
TABLE 125 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023–2035 (USD MILLION) 151
TABLE 126 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023–2035 (USD MILLION) 152
TABLE 127 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY REGION, 2023–2035 (USD MILLION) 152
TABLE 128 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023–2035 (USD MILLION) 152
TABLE 129 RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION) 153
TABLE 130 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION) 154
TABLE 131 EUROPE: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS,
BY COUNTRY, 2023–2035 (USD MILLION) 154
TABLE 132 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION) 155
TABLE 133 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION) 155
TABLE 134 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION) 155
TABLE 135 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION) 156
TABLE 136 RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION,
2023–2035 (USD MILLION) 156
TABLE 137 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2035 (USD MILLION) 157
TABLE 138 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 157
TABLE 139 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2035 (USD MILLION) 158
TABLE 140 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2035 (USD MILLION) 158
TABLE 141 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY REGION, 2023–2035 (USD MILLION) 158
TABLE 142 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2035 (USD MILLION) 159
TABLE 143 RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 161
TABLE 144 RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION,
2023–2035 (USD MILLION) 162
TABLE 145 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023–2035 (USD MILLION) 162
TABLE 146 EUROPE: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023–2035 (USD MILLION) 163
TABLE 147 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023–2035 (USD MILLION) 163
TABLE 148 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023–2035 (USD MILLION) 164
TABLE 149 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION,
2023–2035 (USD MILLION) 164
TABLE 150 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY,
2023–2035 (USD MILLION) 165
TABLE 151 RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION) 166
TABLE 152 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 166
TABLE 153 EUROPE: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 167
TABLE 154 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 167
TABLE 155 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 168
TABLE 156 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION) 168
TABLE 157 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 168
TABLE 158 RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION,
2023–2035 (USD MILLION) 169
TABLE 159 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2035 (USD MILLION) 170
TABLE 160 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION) 170
TABLE 161 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2035 (USD MILLION) 171
TABLE 162 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2035 (USD MILLION) 171
TABLE 163 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY REGION, 2023–2035 (USD MILLION) 171
TABLE 164 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2035 (USD MILLION) 172
TABLE 165 RADIOLIGAND THERAPY MARKET, BY REGION, 2023–2035 (USD MILLION) 174
TABLE 166 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 176
TABLE 167 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 177
TABLE 168 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 177
TABLE 169 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 178
TABLE 170 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 178
TABLE 171 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 178
TABLE 172 US: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 179
TABLE 173 US: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 180
TABLE 174 US: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 180
TABLE 175 US: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 180
TABLE 176 CANADA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 181
TABLE 177 CANADA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 182
TABLE 178 CANADA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 182
TABLE 179 CANADA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 182
TABLE 180 EUROPE: KEY MACROECONOMIC INDICATORS 184
TABLE 181 EUROPE: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 184
TABLE 182 EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 185
TABLE 183 EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 185
TABLE 184 EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 186
TABLE 185 EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 186
TABLE 186 GERMANY: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 187
TABLE 187 GERMANY: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 187
TABLE 188 GERMANY: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 188
TABLE 189 GERMANY: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 188
TABLE 190 UK: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 189
TABLE 191 UK: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 189
TABLE 192 UK: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 190
TABLE 193 UK: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 190
TABLE 194 FRANCE: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 191
TABLE 195 FRANCE: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 191
TABLE 196 FRANCE: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 192
TABLE 197 FRANCE: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 192
TABLE 198 ITALY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 193
TABLE 199 ITALY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 193
TABLE 200 ITALY: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 194
TABLE 201 ITALY: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 194
TABLE 202 SPAIN: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 195
TABLE 203 SPAIN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 195
TABLE 204 SPAIN: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 196
TABLE 205 SPAIN: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 196
TABLE 206 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 197
TABLE 207 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 197
TABLE 208 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 198
TABLE 209 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 198
TABLE 210 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 200
TABLE 211 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 201
TABLE 212 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 201
TABLE 213 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 202
TABLE 214 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 202
TABLE 215 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 202
TABLE 216 CHINA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 203
TABLE 217 CHINA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 204
TABLE 218 CHINA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 204
TABLE 219 CHINA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 204
TABLE 220 JAPAN: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 205
TABLE 221 JAPAN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 206
TABLE 222 JAPAN: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 206
TABLE 223 JAPAN: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 206
TABLE 224 INDIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 207
TABLE 225 INDIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 208
TABLE 226 INDIA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 208
TABLE 227 INDIA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 208
TABLE 228 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 209
TABLE 229 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 210
TABLE 230 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 210
TABLE 231 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 210
TABLE 232 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 211
TABLE 233 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 212
TABLE 234 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 212
TABLE 235 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 212
TABLE 236 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 213
TABLE 237 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 214
TABLE 238 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 214
TABLE 239 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 214
TABLE 240 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 216
TABLE 241 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 216
TABLE 242 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 217
TABLE 243 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 217
TABLE 244 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 218
TABLE 245 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 218
TABLE 246 BRAZIL: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 219
TABLE 247 BRAZIL: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 219
TABLE 248 BRAZIL: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 220
TABLE 249 BRAZIL: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 220
TABLE 250 MEXICO: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 221
TABLE 251 MEXICO: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 221
TABLE 252 MEXICO: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 222
TABLE 253 MEXICO: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 222
TABLE 254 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 223
TABLE 255 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 223
TABLE 256 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 224
TABLE 257 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 224
TABLE 258 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 226
TABLE 259 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY REGION,
2023–2035 (USD MILLION) 226
TABLE 260 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 227
TABLE 261 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 227
TABLE 262 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 228
TABLE 263 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 228
TABLE 264 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 229
TABLE 265 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 229
TABLE 266 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 230
TABLE 267 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 230
TABLE 268 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 230
TABLE 269 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 231
TABLE 270 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 232
TABLE 271 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 232
TABLE 272 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 232
TABLE 273 UAE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 233
TABLE 274 UAE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 234
TABLE 275 UAE: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 234
TABLE 276 UAE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 234
TABLE 277 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 235
TABLE 278 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 236
TABLE 279 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 236
TABLE 280 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 236
TABLE 281 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 237
TABLE 282 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION) 238
TABLE 283 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 238
TABLE 284 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 238
TABLE 285 AFRICA: KEY MACROECONOMIC INDICATORS 240
TABLE 286 AFRICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION) 240
TABLE 287 AFRICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 241
TABLE 288 AFRICA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION) 241
TABLE 289 AFRICA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION) 241
TABLE 290 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOLIGAND THERAPY MARKET, 2023–2025 242
TABLE 291 RADIOLIGAND THERAPY MARKET: DEGREE OF COMPETITION 245
TABLE 292 RADIOLIGAND THERAPY MARKET: REGION FOOTPRINT 251
TABLE 293 RADIOLIGAND THERAPY MARKET: TARGET FOOTPRINT 252
TABLE 294 RADIOLIGAND THERAPY MARKET: INDICATION FOOTPRINT 252
TABLE 295 RADIOLIGAND THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 255
TABLE 296 RADIOLIGAND THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 256
TABLE 297 RADIOLIGAND THERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 257
TABLE 298 RADIOLIGAND THERAPY MARKET: DEALS, JANUARY 2022–AUGUST 2025 258
TABLE 299 RADIOLIGAND THERAPY MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025 259
TABLE 300 NOVARTIS AG: COMPANY OVERVIEW 260
TABLE 301 NOVARTIS AG: PRODUCTS OFFERED 261
TABLE 302 NOVARTIS AG: PRODUCTS IN PIPELINE 262
TABLE 303 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–AUGUST 2025 262
TABLE 304 NOVARTIS AG: DEALS, JANUARY 2022–AUGUST 2025 262
TABLE 305 NOVARTIS AG: EXPANSIONS, JANUARY 2022–AUGUST 2025 263
TABLE 306 BAYER AG: COMPANY OVERVIEW 265
TABLE 307 BAYER AG: PRODUCTS OFFERED 266
TABLE 308 BAYER AG: DEALS, JANUARY 2022–AUGUST 2025 267
TABLE 309 BAYER AG: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 267
TABLE 310 CURIUM US LLC: COMPANY OVERVIEW 269
TABLE 311 CURIUM US LLC: PRODUCTS IN PIPELINE 269
TABLE 312 CURIUM US LLC: DEALS, JANUARY 2022–AUGUST 2025 269
TABLE 313 ELI LILLY AND COMPANY: COMPANY OVERVIEW 271
TABLE 314 ELI LILLY AND COMPANY: PRODUCTS IN PIPELINE 272
TABLE 315 ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022– AUGUST 2025 273
TABLE 316 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–AUGUST 2025 273
TABLE 317 ASTRAZENECA: COMPANY OVERVIEW 275
TABLE 318 ASTRAZENECA: PRODUCTS IN PIPELINE 276
TABLE 319 ASTRAZENECA: DEALS, JANUARY 2022–AUGUST 2025 277
TABLE 320 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY OVERVIEW 278
TABLE 321 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): PRODUCTS IN PIPELINE 279
TABLE 322 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): DEALS,
JANUARY 2022–AUGUST 2025 279
TABLE 323 ARICEUM THERAPEUTICS: COMPANY OVERVIEW 280
TABLE 324 ARICEUM THERAPEUTICS: PRODUCTS IN PIPELINE 280
TABLE 325 ARICEUM THERAPEUTICS: DEALS, JANUARY 2022–AUGUST 2025 280
TABLE 326 TELIX PHARMACEUTICALS: COMPANY OVERVIEW 281
TABLE 327 TELIX PHARMACEUTICALS: PRODUCTS IN PIPELINE 282
TABLE 328 TELIX PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025 283
TABLE 329 TELIX PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–AUGUST 2025 283
TABLE 330 TELIX PHARMACEUTICAL: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 283
TABLE 331 ITM ISOTOPE TECHNOLOGIES: COMPANY OVERVIEW 284
TABLE 332 ITM ISOTOPE TECHNOLOGIES: PRODUCTS OFFERED 284
TABLE 333 ITM ISOTOPE TECHNOLOGIES: DEALS, JANUARY 2022–AUGUST 2025 285
TABLE 334 ITM ISOTOPE TECHNOLOGIES: EXPANSIONS, JANUARY 2022–AUGUST 2025 286
TABLE 335 CONVERGENT THERAPEUTICS, INC.: COMPANY OVERVIEW 287
TABLE 336 CONVERGENT THERAPEUTICS, INC.: PRODUCTS IN PIPELINE 287
TABLE 337 CONVERGENT THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 287
TABLE 338 CONVERGENT THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025 288
TABLE 339 ORANO SA: COMPANY OVERVIEW 289
TABLE 340 ORANO SA: PRODUCTS IN PIPELINE 290
TABLE 341 ORANO SA: DEALS, JANUARY 2022–AUGUST 2025 291
TABLE 342 ORANO SA: EXPANSIONS, JANUARY 2022–AUGUST 2025 291
TABLE 343 ACTINIUM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 292
TABLE 344 ACTINIUM PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE 293
TABLE 345 ACTINIUM PHARMACEUTICALS, INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 293
TABLE 346 ACTINIUM PHARMACEUTICALS, INC.: DEALS, JANUARY 2022–AUGUST 2025 293
TABLE 347 PERSPECTIVE THERAPEUTICS, INC.: COMPANY OVERVIEW 294
TABLE 348 PERSPECTIVE THERAPEUTICS, INC.: PRODUCTS IN PIPELINE 294
TABLE 349 PERSPECTIVE THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025 295
TABLE 350 CLARITY PHARMACEUTICALS: COMPANY OVERVIEW 296
TABLE 351 CLARITY PHARMACEUTICALS: PRODUCTS IN PIPELINE 297
TABLE 352 CLARITY PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025 297
TABLE 353 CLARITY PHARMACEUTICALS: OTHER DEVELOPMENTS,
JANUARY 2022–AUGUST 2025 297
TABLE 354 RADIOPHARM THERANOSTICS LTD.: COMPANY OVERVIEW 298
TABLE 355 RADIOPHARM THERANOSTICS LTD.: PRODUCTS IN PIPELINE 298
TABLE 356 RADIOPHARM THERANOSTICS LTD.: DEALS, JANUARY 2022–AUGUST 2025 299
TABLE 357 ALPHA 9 ONCOLOGY: COMPANY OVERVIEW 300
TABLE 358 RATIO THERAPEUTICS: COMPANY OVERVIEW 300
TABLE 359 NORIA THERAPEUTICS: COMPANY OVERVIEW 301
TABLE 360 PRECIRIX: COMPANY OVERVIEW 301
TABLE 361 SOFIE: COMPANY OVERVIEW 302
TABLE 362 ECKERT & ZIEGLER RADIOPHARMA: COMPANY OVERVIEW 302
TABLE 363 NORTHSTAR MEDICAL RADIOISOTOPES, LLC: COMPANY OVERVIEW 303
TABLE 364 IRE- IRE ELIT: COMPANY OVERVIEW 303
TABLE 365 BWXT MEDICAL LTD.: COMPANY OVERVIEW 304
TABLE 366 NTP RADIOISOTOPES: COMPANY OVERVIEW 304
LIST OF FIGURES
FIGURE 1 RADIOLIGAND THERAPY MARKET SEGMENTATION AND REGIONAL SCOPE 32
FIGURE 2 RADIOLIGAND THERAPY MARKET: YEARS CONSIDERED 33
FIGURE 3 RADIOLIGAND THERAPY MARKET: RESEARCH DESIGN 35
FIGURE 4 RADIOLIGAND THERAPY MARKET: KEY DATA FROM SECONDARY SOURCES 37
FIGURE 5 RADIOLIGAND THERAPY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 38
FIGURE 6 RADIOLIGAND THERAPY MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 39
FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2030 40
FIGURE 8 REVENUE SHARE ANALYSIS OF NOVARTIS, 2024 40
FIGURE 9 RADIOLIGAND THERAPY MARKET SIZE VALIDATION FROM PRIMARY SOURCES 42
FIGURE 10 RADIOLIGAND THERAPY MARKET: TOP-DOWN APPROACH 43
FIGURE 11 RADIOLIGAND THERAPY MARKET: CAGR PROJECTIONS 44
FIGURE 12 RADIOLIGAND THERAPY MARKET: DATA TRIANGULATION 46
FIGURE 13 RADIOLIGAND THERAPY MARKET: GLOBAL MARKET SIZE, GROWTH
RATE, AND FORECAST 49
FIGURE 14 RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2025 VS. 2035 (USD MILLION) 51
FIGURE 15 RADIOLIGAND THERAPY MARKET, BY TARGET, 2025 VS. 2035 (USD MILLION) 52
FIGURE 16 RADIOLIGAND THERAPY MARKET, BY INDICATION, 2025 VS. 2035 (USD MILLION) 52
FIGURE 17 RADIOLIGAND THERAPY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION) 53
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF RADIOLIGAND THERAPY MARKET 54
FIGURE 19 INCREASING APPROVALS AND LABEL EXPANSION OF RLT PRODUCTS
TO DRIVE MARKET 55
FIGURE 20 LUTETIUM‑177 VIPIVOTIDE TETRAXETAN SEGMENT AND US TO LEAD NORTH AMERICAN MARKET IN 2024 56
FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 57
FIGURE 22 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATE DURING
FORECAST PERIOD 58
FIGURE 23 RADIOLIGAND THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 61
FIGURE 24 NEW REVENUE POCKETS FOR PLAYERS IN RADIOLIGAND THERAPY MARKET 67
FIGURE 25 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS,
BY KEY PLAYER, 2024 68
FIGURE 26 INDICATIVE PRICING ANALYSIS, BY REGION, 2024 69
FIGURE 27 RADIOLIGAND THERAPY MARKET: VALUE CHAIN ANALYSIS 70
FIGURE 28 RADIOLIGAND THERAPY MARKET: ECOSYSTEM ANALYSIS 72
FIGURE 29 RADIOLIGAND THERAPY MARKET: INVESTMENT AND FUNDING SCENARIO,
2023–2024 73
FIGURE 30 RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 81
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND
THERAPY PRODUCTS 83
FIGURE 32 KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY PRODUCTS, BY END USER 84
FIGURE 33 RADIOLIGAND THERAPY MARKET: AI USE CASES 91
FIGURE 34 NORTH AMERICA: RADIOLIGAND THERAPY MARKET SNAPSHOT 176
FIGURE 35 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET SNAPSHOT 200
FIGURE 36 RADIOLIGAND THERAPY MARKET: REVENUE ANALYSIS OF KEY PLAYERS,
2028–2030 (USD MILLION) 244
FIGURE 37 RADIOLIGAND THERAPY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2030 245
FIGURE 38 EV/EBITDA OF KEY VENDORS 246
FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 247
FIGURE 40 RADIOLIGAND THERAPY MARKET: BRAND/PRODUCT COMPARISON 247
FIGURE 41 RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 249
FIGURE 42 RADIOLIGAND THERAPY MARKET: COMPANY FOOTPRINT 250
FIGURE 43 RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 254
FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024) 261
FIGURE 45 BAYER AG: COMPANY SNAPSHOT (2024) 266
FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024) 272
FIGURE 47 ASTRAZENECA: COMPANY SNAPSHOT (2024) 276
FIGURE 48 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY SNAPSHOT (2024) 278
FIGURE 49 TELIX PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 282
FIGURE 50 ORANO SA: COMPANY SNAPSHOT (2024) 290
FIGURE 51 ACTINIUM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023) 292
FIGURE 52 CLARITY PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 296
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 精密林業市場規模、シェア、動向、2030年までの世界予測 2025-11-05
- フィールドサービス管理市場規模、シェア、動向、2030年までの世界予測 2025-11-05
- 採血装置市場規模、シェア、動向、2030年までの世界予測 2025-11-04
- 車載半導体市場規模、シェア、動向、2030年までの世界予測 2025-11-04
- データセンターUPS市場規模、シェア、動向、2030年までの世界予測 2025-10-31